Dimerix (ASX:DXB) Total Liabilities: A$66.24 Mil (As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.19
! 3 Warning Signs
View Full Analysis

What is Dimerix Total Liabilities?

Dimerix ASX:DXB -5.00% 32 Total Liabilities is A$66.24 Mil as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Dimerix's Total Liabilities for the quarter that ended in Dec. 2025 was A$66.24 Mil.

Dimerix's quarterly Total Liabilities increased from Dec. 2024 (A$14.74 Mil) to Jun. 2025 (A$77.80 Mil) but then declined from Jun. 2025 (A$77.80 Mil) to Dec. 2025 (A$66.24 Mil).

Dimerix's annual Total Liabilities increased from Jun. 2023 (A$11.79 Mil) to Jun. 2024 (A$13.89 Mil) and increased from Jun. 2024 (A$13.89 Mil) to Jun. 2025 (A$77.80 Mil).

Dimerix Total Liabilities Historical Data

* Premium members only.

The historical data trend for Dimerix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix Total Liabilities Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.95 2.07 11.79 13.89 77.80

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.37 13.89 14.74 77.80 66.24
ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Dimerix's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.157+(0+55.58
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.029+0.032+0)
=77.80

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=91.177-13.379
=77.80

Dimerix's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.732+(0+53.501
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.009+0+0)
=66.24

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=64.561--1.681
=66.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$66.24 Mil mean?
Dimerix (ASX:DXB) has a Total Liabilities of A$66.24 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Dimerix and its competitors.
Is Dimerix's Total Liabilities too high?
Dimerix's current Total Liabilities is A$66.24 Mil. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Total Liabilities compare to VRTX and REGN?
Dimerix's Total Liabilities of A$66.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Dimerix and its competitors. Dimerix's current Total Liabilities is A$66.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Total Liabilities of A$66.24 Mil. The current Total Liabilities is A$66.24 Mil. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Total Liabilities is A$66.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.19
Price